Japan's Kinish raises $3.09M to turn rice into dairy alternatives
What's the deal? Tokyo-based startup KinishDealroom has a profile for this one. Try Dealroom → has raised US$3.77M (roughly $3.09 million) in the first close of its Series A round. Investors include INSPiRE Mutualistic Symbiosis Fund 1, Shimadzu Future Innovation FundDealroom has a profile for this one. Try Dealroom →, Obayashi CorporationDealroom has a profile for this one. Try Dealroom →, and Canada's Love Veggies Holding Ltd.
What's the endgame? Kinish develops dairy alternatives built from rice. Its near-term product, a plant-based ice cream called The Rice Creamery, sells in about 500 stores across Japan. Longer term, it is engineering rice plants to express casein, a milk protein, through molecular farming.
Where's the money going? The funding will expand sales of The Rice Creamery in Japan and the US, fund research into vertical farming and molecular farming, and support hiring. Kinish has opened a New York office to grow local production, retail distribution, and brand awareness.
The company frames the work against climate pressure on dairy. Rising temperatures strain milk supply, as heat stress cuts yields in cows, while milk production adds greenhouse gas emissions and heavy demands on feed and water.
Why now? The round builds on a US$923.1K seed raise in 2025 and follows the October launch of The Rice Creamery at retailers and a Meta office in Washington, DC. Kinish says it has produced casein in rice and, in a vertical-farming trial, harvested short-stalk rice plants at 2,079.7g per square metre over three months — far above the roughly 539g from a single annual open-field crop.
What could go wrong? The technology that sets Kinish apart remains unproven at scale. Its rice-derived casein still needs to reach commercial production, and the current ice cream uses conventional domestic rice, not the company's engineered variety.
The signal: The US$3.77M first close sits in the lower range of comparable rounds, in the 19th percentile by amount. For Kinish, the near-term test is less the headline figure than its progress on US sales and scaling milk-protein production.
Read more: prtimes.jp
Image credit: Eric Pesik and Deanna Pesik
